Journal
ONCOTARGET
Volume 7, Issue 10, Pages 10773-10787Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.7387
Keywords
metformin; endothelial dysfunction; oxLDL; SIRT1; Gerotarget
Categories
Funding
- Ministry of Science and Technology [MOST-103-2320-B-006-050]
- National Cheng Kung University [NSC 100-2314-B-039-017-MY3, MOST 103-2320-B-006-050, D103-35A13]
- [CMU103-N-14]
- [CMU104-N-02]
Ask authors/readers for more resources
It is suggested that oxLDL is decisive in the initiation and development of atherosclerotic injuries. The up-regulation of oxidative stress and the generation of ROS act as key modulators in developing pro-atherosclerotic and anti-atherosclerotic processes in the human endothelial wall. In this present study, we confirmed that metformin enhanced SIRT1 and AMPK expression in human umbilical vein endothelial cells (HUVECs). Metformin also inhibited oxLDL-increased LOX-1 expression and oxLDL-collapsed AKT/eNOS levels. However, silencing SIRT1 and AMPK diminished the protective function of metformin against oxidative injuries. These results provide a new insight regarding the possible molecular mechanisms of metformin.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available